The U.S. Food and Drug Administration (FDA) has recently given approval for the first over-the-counter (OTC) glucometer that can be used in conjunction with an Apple iPhone to monitor blood sugar levels. This groundbreaking development offers individuals a new way to keep track of their glucose without the need for a prescription. Nonetheless, there are specific stipulations and restrictions that should be noted, particularly for those with diabetes.
With the FDA’s approval of this device, Apple iPhone users interested in managing their blood sugar levels can now acquire a medically sanctioned device without the necessity of a doctor’s prescription. However, users should be aware of certain limitations associated with this technology.
FDA Clears Dexcom Stelo Glucose Biosensor System for OTC Use
In a significant move, the FDA has given its approval to Dexcom’s Stelo, a Glucose Biosensor System, for usage as an OTC iCGM glucometer. This device functions via a wearable sensor that establishes a Bluetooth connection with an iPhone.
The Dexcom Stelo Glucose Biosensor System is distinguished as an integrated CGM (iCGM), meaning it relies on continuous connectivity to the corresponding iPhone to log glucose readings, which it does at 15-minute intervals. This system necessitates attaching a patch to the user’s arm.
Each sensor is designed to last approximately 15 days before it needs to be replaced. Users are required to install a dedicated application from the Apple App Store and pair it with the sensor to access their readings. Although the FDA announcement alludes to potential compatibility with “other smart devices,” further details have not been disclosed.
Originally, the developers behind the Stelo glucometer aimed to allow synchronization with an Apple Watch. This functionality may be provided in the future, but as of now, only users with an iPhone can use Stelo to monitor their blood glucose.
Understanding Stelo’s Role for Non-Diabetics in Tracking Glucose Levels
The Stelo system comprises a wearable sensor and an accompanying smartphone app, enabling real-time monitoring of glucose levels for any individual with an iPhone. This system presents a convenient method for logging glucose readings throughout the day.
In a critical advisory, the FDA has emphasized that Stelo iCGM is not designed for diabetic patients, particularly those who are managing their diabetes through oral medications. The system is approved for use by adults interested in understanding how their lifestyle choices, such as diet and exercise, affect their blood sugar levels. Furthermore, the system is not intended for those with chronic hypoglycemia, as it does not offer alerts for this perilous condition.
While numerous smartwatches and wearable devices claim to provide non-invasive blood glucose measurement, the FDA advises caution and emphasizes that these gadgets should not be relied upon for medical advice due to their lack of proven reliability. For diabetic patients, Dexcom’s Stelo might not be the ideal option as it is restricted in such a medical context.
